The Durability of Anti-TNF Therapy for Crohn’s Disease Is Higher in Anti-TNF Naïve Patients and Increases With Proactive Therapeutic Drug Monitoring
Crohn's & Colitis 360 · 10.04.2025 · 7 (2)
DOI: 10.1093/crocol/otaf028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Crohn's & Colitis 360, online erschienen am 09.04.2025. Verfasst von Robert Gilmore und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, St Vincent's Hospital, Melbourne, Australia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Antitumor necrosis factor (TNF) dose escalation is performed to improve therapeutic response and optimize outcomes in patients with Crohn’s disease (CD). We aimed to describe the durability of anti-TNF therapy in patients with CD receiving escalated anti-TNF therapy, along with the overall durability of anti-TNF treatment between patients managed with a proactive versus reactive therapeutic drug monitoring (TDM) approach.
Methods
We undertook a retrospective multicentre cohort study. One center practiced proactive TDM with a weekly virtual TDM clinic, while the other practiced reactive TDM. Patients receiving escalated infliximab or adalimumab therapy for CD from January 2015 to April 2022 were included. Durability was defined as the time from biologic start to cessation for treatment failure.
Results
239 patients (45% female, median age 39) meeting criteria for inclusion were identified; 165 patients were included in the proactive TDM cohort and 74 in the reactive TDM cohort. Anti-TNF naïve patients had significantly higher durability of therapy when compared with the anti-TNF exposed patients for both overall durability (P = .045) and durability postescalation (P = .017). The proactive TDM cohort had significantly higher durability when compared with the reactive cohort for both overall durability (P = .001) and durability postescalation (P = .002).
Conclusions
This multicentre, retrospective cohort study illustrates the importance of dose escalation as a therapeutic strategy in IBD care. The durability of anti-TNF therapy is superior in anti-TNF naïve compared to exposed patients and can be improved further by proactive TDM to guide dose optimization.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, St Vincent's Hospital, Melbourne, Australia.
- Department of Gastroenterology, Mater Hospital, Brisbane, Australia.
- Mater Research Institute, University of Queensland, South Brisbane, Australia.
- Department of Medicine, University of Melbourne, Melbourne, Australia.
ORCID-Profile: Robert Gilmore, Aathavan Shanmuga Anandan, Jakob Begun, Emily K Wright
Zitieren
APA
Gilmore, R., Fernandes, R., Schildkraut, T., Joshi, R., Lin, L., Vorgin, S., Etchegaray, A., Shanmuga Anandan, A., Tambakis, G., Loebenstein, M., An, Y. K., Begun, J., & Wright, E. K. (2025). The Durability of Anti-TNF Therapy for Crohn’s Disease Is Higher in Anti-TNF Naïve Patients and Increases With Proactive Therapeutic Drug Monitoring. Crohn's & Colitis 360, 7(2). https://doi.org/10.1093/crocol/otaf028
Vancouver
Gilmore R, Fernandes R, Schildkraut T, Joshi R, Lin L, Vorgin S, et al. The Durability of Anti-TNF Therapy for Crohn’s Disease Is Higher in Anti-TNF Naïve Patients and Increases With Proactive Therapeutic Drug Monitoring. Crohn's & Colitis 360. 2025;7(2). doi:10.1093/crocol/otaf028
BibTeX
@article{Gilmore2025,
author = {Gilmore, Robert and Fernandes, Richard and Schildkraut, Tamar and Joshi, Riddhi and Lin, Lyman and Vorgin, Sara and Etchegaray, Amirah and Shanmuga Anandan, Aathavan and Tambakis, George and Loebenstein, Moshe and An, Yoon-Kyo and Begun, Jakob and Wright, Emily K},
title = {The Durability of Anti-TNF Therapy for Crohn’s Disease Is Higher in Anti-TNF Naïve Patients and Increases With Proactive Therapeutic Drug Monitoring},
journal = {Crohn's & Colitis 360},
year = {2025},
volume = {7},
number = {2},
doi = {10.1093/crocol/otaf028}
}
EUVIMED